# reload+after+2024-01-20 02:45:31.162981
address1§100 Summer Street
address2§Suite 2300
city§Boston
state§MA
zip§02110
country§United States
phone§617 621 7722
fax§617 494 0480
website§https://www.ironwoodpharma.com
industry§Drug Manufacturers—Specialty & Generic
sector§Healthcare
longBusinessSummary§Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
fullTimeEmployees§219
companyOfficers§[{'maxAge': 1, 'name': 'Ms. Julie H. McHugh', 'age': 59, 'title': 'Executive Chairman of the Board', 'yearBorn': 1964, 'fiscalYear': 2022, 'totalPay': 95000, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Thomas A. McCourt', 'age': 66, 'title': 'CEO & Director', 'yearBorn': 1957, 'fiscalYear': 2022, 'totalPay': 1420197, 'exercisedValue': 0, 'unexercisedValue': 1031816}, {'maxAge': 1, 'name': 'Mr. Sravan Kumar Emany', 'age': 45, 'title': 'Senior VP, Principal Financial Officer & CFO', 'yearBorn': 1978, 'fiscalYear': 2022, 'totalPay': 712362, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Minardo', 'age': 47, 'title': 'Senior VP, Chief Legal Officer & Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 675885, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael  Shetzline M.D., Ph.D.', 'age': 64, 'title': 'Chief Medical Officer, Senior VP and Head of Research & Drug Development', 'yearBorn': 1959, 'fiscalYear': 2022, 'totalPay': 837742, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Ronald  Silver', 'age': 41, 'title': 'Corporate Controller & Principal Accounting Officer', 'yearBorn': 1982, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Marcel  Moulaison', 'title': 'Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Greg  Martini', 'title': 'Vice President of Strategic Finance & Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Beth  Calitri', 'title': 'Head of Corporate Communications & Media Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Mike  Nanfito', 'title': 'Vice President of Sales & Sales Excellence', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§5
boardRisk§3
compensationRisk§1
shareHolderRightsRisk§6
overallRisk§3
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.728
priceToSalesTrailing12Months§4.495586
currency§USD
dateShortInterest§1702598400
forwardEps§0.79
pegRatio§-0.03
exchange§NMS
quoteType§EQUITY
shortName§Ironwood Pharmaceuticals, Inc.
longName§Ironwood Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1265207400
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§bbecc65d-4c04-3cd5-be4a-aec950ecb433
gmtOffSetMilliseconds§-18000000
targetHighPrice§22.0
targetLowPrice§9.0
targetMeanPrice§17.83
targetMedianPrice§20.0
recommendationMean§1.9
recommendationKey§buy
numberOfAnalystOpinions§6
quickRatio§0.837
earningsGrowth§-0.685
grossMargins§0.82456
ebitdaMargins§0.5421
trailingPegRatio§None
